Verastem, Inc.
Clinical trials sponsored by Verastem, Inc., explained in plain language.
A biopharmaceutical company developing drugs to treat cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets Hard-to-Treat lung cancer mutation Results expected Jun 2027 (estimated) May already have reported ↗
- New pill targets stubborn colorectal cancer mutation Results expected Jun 2027 (estimated) May already have reported ↗
- New pill targets tough pancreatic cancer mutation Results expected Jun 2027 (estimated) May already have reported ↗
- Can a Two-Drug combo keep fighting a rare ovarian cancer? Results expected Aug 2027 (estimated)
-
New pill targets Hard-to-Treat lung cancer mutation
Disease control Recruiting nowThis trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill targets stubborn colorectal cancer mutation
Disease control Recruiting nowThis study tests an experimental pill called VS-7375, designed to block a specific cancer-driving protein (KRAS G12D). The trial includes people with metastatic colorectal cancer that has this mutation. Some participants receive VS-7375 alone, others get it combined with an antib…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets tough pancreatic cancer mutation
Disease control Recruiting nowThis study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…
Phase 3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…
Phase 1/2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC